Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans multiple ...
Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...
Vertex Pharmaceuticals Incorporated is a $120bn market cap pharma giant with a successful CF franchise, growing revenues from $1bn in 2015 to $9.9bn in 2023. Vertex gained approval for its first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results